Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of 208 genes.

Cutaneous lymphomas T-cell lymphoma gene expression profiling lupus erythematosus lupus erythematosus panniculitis subcutaneous panniculitis-like T-cell lymphoma

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
09 2021
Historique:
pubmed: 11 5 2021
medline: 25 2 2023
entrez: 10 5 2021
Statut: ppublish

Résumé

Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare cytotoxic cutaneous lymphoma. Differential diagnosis with lupus erythematosus panniculitis (LEP) can be challenging and overlapping cases have been described. In this study, we investigate whether gene expression profiling may or not identify markers that can be used to improve our understanding of the disease and to make a precise differential diagnosis. SPTCL, LEP, and overlapping cases were analyzed using a customized NanoString platform including 208 genes related to T-cell differentiation, stromal signatures, oncogenes, and tumor suppressor genes. Gene expression unsupervised analysis of the samples differentiated SPTCL from LEP samples. Most overlapping cases were clustered with LEP cases. Differentially expressed genes were observed when comparing SPTCL with LEP cases; and overlapping with LEP cases. Gene set enrichment analysis recognized gene sets defining each group. In conclusion, SPTCL and LEP have distinctive molecular profiles and the molecular background of overlapping cases more closely resembles LEP.

Identifiants

pubmed: 33966586
doi: 10.1080/10428194.2021.1901098
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2130-2140

Auteurs

Salma Machan (S)

Department of Dermatology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.

Marta Rodríguez (M)

Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.
CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Madrid, Spain.

Ruth Alonso-Alonso (R)

Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.
CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Madrid, Spain.

Rebeca Manso (R)

Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.
CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Madrid, Spain.

Sandra Pérez-Buira (S)

Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.
CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Madrid, Spain.

Jennifer Borregón (J)

Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.
CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Madrid, Spain.

José Luis Rodríguez-Peralto (JL)

Hospital Universitario 12 de Octubre, Madrid, Spain.

Lorenzo Cerroni (L)

Department of Dermatology, Dermatopathology Research Unit, Medical University of Graz, Graz, Austria.

Rosario Haro (R)

Department of Dermatology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.

Candelaria García (C)

Hospital Universitario de Canarias, Tenerife, Spain.

Enrique García Toro (E)

Hospital Universitario de Burgos, Burgos, Spain.

Teresa Estrach (T)

Hospital Clínic de Barcelona, Barcelona, Spain.

Adriana García-Herrera (A)

Hospital Clínic de Barcelona, Barcelona, Spain.

Berta Ferrer (B)

Hospital Vall d'Hebron, Barcelona, Spain.

Carlos González-Cruz (C)

Hospital Vall d'Hebron, Barcelona, Spain.

Nerea Segues (N)

Hospital Universitario Donostia, San Sebastián, Spain.

Juan Luis Afonso-Martin (JL)

Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain.

Yeray Peñate (Y)

Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain.

Carlos Monteagudo (C)

Hospital Clínico Universitario de Valencia, Universidad de Valencia, Valencia, Spain.

Miguel Ángel Limeres-Gonzalez (MÁ)

Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain.

María Ángeles González-Núñez (MÁ)

Hospital Ciudad de Coria y Hospital San Pedro de Alcántara, Cáceres, Spain.

Maria Ángeles Torres-Nieto Torres (MÁT)

Hospital Universitario Río Hortega, Valladolid, Spain.

Laura Cereceda (L)

Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.
CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Madrid, Spain.

Raúl Córdoba (R)

Department of Hematology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.

Miguel Ángel Piris (MÁ)

Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.
CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Madrid, Spain.

Luis Requena (L)

Department of Dermatology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.

Socorro María Rodríguez-Pinilla (S)

Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.
CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH